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Background: As the clinical significance of chronic bronchitis among smokers without airflow
obstruction is unclear, we sought to determine morbidity associated with this disorder.
Methods: We examined subjects from the COPDGene study and compared those with FEV1/FVC
0.70, no diagnosis of asthma and chronic bronchitis as defined as a history of cough and phlegm
productionfor3months/year for2years (NCB) tonon-obstructedsubjectswithoutchronicbron-
chitis (CB-).Multivariate analysis was used to determine factors associatedwith and impact ofNCB.
Results: We identified597NCB and 4283 CB- subjects. NCBparticipantswere younger (55.4 vs. 57.2
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NCB non-obstructive chr
CB- chronic bronchitis s
FEV1 forced expiratory vo
second
FVC forced vital capacit
SGRQ Saint-George’s Resp
Questionnaire
GERD gastro-esophageal r
COPD chronic obstructive
QOL quality-of-life
GOLD Global Initiative for
Disease
NHANESNational Health and
Examination Survey
SF-36 Short Form Health S
SF-36 PCS physical compon
36
SF-36 MCS mental compone
BMI body mass index
MMRC Modified Medical Re
Dyspnea Score
6MWD six-minute walking
OR odds ratio
OSA obstructive sleep ap
MCID minimal clinically imoften current smokers;more frequently reported occupational exposure to fumes (52.8% vs. 42.2%,
p< 0.001), dust for1year (55.3%vs. 42.0%,p< 0.001)andwere less likely tobecurrentlyworking.
NCB subjects demonstrated worse quality-of-life (SGRQ 35.6 vs. 15.1, p < 0.001) and exercise ca-
pacity (walk distance 415 vs. 449 m, p < 0.001) and more frequently reported respiratory “flare-
ups” requiring treatment with antibiotics or steroids (0.30 vs. 0.10 annual events/subject,
p < 0.001) prior to enrollment and during follow-up (0.34 vs. 0.16 annual events/subject,
p < 0.001). In multivariate analysis, current smoking, GERD, sleep apnea and occupational expo-
sures were significantly associated with NCB.
Conclusions: While longitudinal datawill be needed todeterminewhetherNCBprogresses toCOPD,
NCBpatientshavepoorerquality-of-life,exercisecapacityand frequent respiratoryevents.Beyond
smoking cessation interventions, further research is warranted to determine the benefit of other
therapeutics in this population.
Clinical Trials Registration # NCT00608764 (http://clinicaltrials.gov/show/NCT00608764).
Link to study protocol: http://www.copdgene.org/sites/default/files/COPDGeneProtocol-5-0_
06-19-2009.pdf.
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The pathways involved in the development of COPD and
lung cancer after exposure to tobacco smoke involve airway
inflammation, oxidative damage and impaired repair [1,2].
Chronic cough and phlegm in smokers have also been
correlated with pathologic, functional, and molecular sig-
natures of chronic inflammation [3e5]. Cross-sectionalstudies have validated the existence of a chronic bron-
chitis phenotype among smokers with established airway
obstruction [6,7]. While several population based studies
have reported poorer quality-of-life (QOL), more frequent
infections and accelerated lung function decline [8e11] in
these patients, the impact of chronic bronchitis in those
without airflow obstruction is less clear. Epidemiologic
studies suggest chronic bronchitis is a risk factor for inci-
dental airflow obstruction, but mainly within subjects
younger than 50 years of age [8]. Therefore is possible that
in some patients, non-obstructive chronic bronchitis (NCB)
is an early presentation of COPD whereas in others it may
be a distinct disorder. In the absence of airflow obstruction,
however, this group of patients is typically overlooked with
respect to assessment and the development of treatments.
Using participants from the COPDGene study who were all
current or former smokers without airflow obstruction and
without history of asthma, in a cross-sectional design and
with additional follow-up for two years, we hypothesized
that when compared to those without chronic bronchitis
symptoms, subjects with non-obstructive chronic bronchitis
(NCB) would have worse quality of life, poorer exercise
tolerance and more frequent respiratory events at baseline
and during follow-up.Methods
Patient selection
Briefly, the COPDGene Study (http://www.copdgene.org/),
described in detail previously [12] is a NHLBI-funded multi-
center investigation of the genetic epidemiology of
smoking-related lung disease, which recently completed
inclusion of the baseline cohort of more than 10,000 par-
ticipants (Clinical Trials Registration # NCT00608764). Sub-
jects were enrolled between January 2008 and June 2011.
Inclusion criteria include ability to give informed consent;
age 45e80 years; cigarette smoking 10 pack years; and
willingness to undergo study-related testing including
spirometry and a chest CT scan. For our analysis, all subjects
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meeting GOLD criteria for COPD (absence of airflow
obstruction with a post-bronchodilator FEV1/FVC (forced
vital capacity) ratio 0.7), with no history of physician-
diagnosed asthma, selected from the full COPDGene
cohort of 10,276 individuals. This research protocol was
approved by the institutional review board at each partici-
pating institution (University of Michigan Health System
Research Committee IRB approval HUM000014973, 07/16/
2010). All participants provided written informed consent.
Data collection
Self-administered questionnaires were used to collect de-
mographic data, smoking, occupational exposures and
medical history. Coexistent diseases and chronic conditions
were self-reported. Participants were presented with the
question “Have you ever been told by a physician that you
have.” and a list of different diseases. The MMRC scale
was used to evaluate the degree of dyspnea [13]. Patients
underwent spirometry using the EasyOne spirometry sys-
tem (Zurich, Switzerland) before and after the adminis-
tration of short-acting bronchodilator (albuterol). NHANES
III data was used as predictive values [14], and quality
control was performed for spirometry tests with both an
automated system and manual review.
Health-related quality-of-life measurements
We included two QOL measures widely used in respiratory
medicine research: the SGRQ total score and sub-scores
(impact, symptoms, activity) [15], and the Short Form-36
Health Survey (SF-36), with its physical component (SF-36
PCS) and mental component scores (SF-36 MCS) [16]. SGRQ
scores range from 0 to 100; higher scores indicate more
severe impact. SF-36 scores are reported from 0 to 100,
with lower scores indicating more limitations. Although
SGRQ is a QOL instrument used mainly among COPD pa-
tients, there are reports of it use in “healthy smokers” and
persons without airway obstruction [17,18]. Results of SGRQ
were available for all participants. SF-36 was implemented
after the study was initiated; henceforth the results were
available for 2663 participants. Participants who responded
to SF-36 were more frequently of female gender and older,
and less frequently of African American race and current
smokers. To account for these differences, all sociodemo-
graphic variables were maintained as covariates in models
examining differences in QOL, measured by SF-36. The
differences between participants with and without data on
SF-36 are presented in the Supplementary Files. The clini-
cally important difference for SF-36 is 4e6 points for
analysis of groups [19,20].
Definition of chronic bronchitis and respiratory
events
The definition of chronic bronchitis was based on baseline
history of cough and phlegm production for 3 consecutive
months per years for two or more years, derived from a
modified form of the American Thoracic Society Diffuse
Lung Disease 1978 Respiratory Epidemiology questionnaire[21]. In this manner subjects meeting these criteria were
classified as NCB vs. those not meeting these criteria, CB-.
Respiratory events were defined by use of antibiotic and/or
steroid or hospital admission for a respiratory “flare-up”.
Prospective respiratory event data was captured through a
longitudinal follow-up protocol conducted every six months
by an automated telephonic or web based inquiry. Subjects
not reached by the automated system were contacted by a
research coordinator. October, 31 2012 was used as the
cutoff date for available longitudinal data.Statistical analysis
Descriptive statistics with proportions, or means and their
standard deviation were used, when appropriate, to
describe demographics, lung function, symptoms, individ-
ual comorbidities, and their score. The impact of de-
mographics, socioeconomic characteristics, prior
occupational exposures, and tobacco use on the presence
of chronic bronchitis was evaluated with stepwise forward
selection logistic regression models where gender, age,
BMI, high school education (a relevant descriptor of socio-
economic status in America), smoking status, tobacco pack-
years, FEV1% and clinical center were required model ele-
ments. Zero inflated negative binomial regression was used
to model respiratory events due to their skewed distribu-
tion with zero events being most frequent. The indepen-
dent effect of chronic bronchitis on dyspnea, walking
distance, and measures of QOL was evaluated with multi-
variate models adjusted for gender, age, BMI, current
smoking, pack-years, FEV1% predicted and clinical center.
The selection of the covariates for the multivariate models
was based on their known roles in determining impact and
outcomes in COPD. All statistical analyses were conducted
using SAS 9.2 statistical software (SAS Corporation, Cary,
N.C.). p-Values <0.05 were considered significant.Results
Of 4880 subjects with a post-bronchodilator FEV1/FVC ratio
0.7 and no history of asthma, 597 (12.2%) met criteria for
NCB and 4283 did not, CB-. Table 1 shows demographic
characteristics, lung function, respiratory exposures, and
comorbidities stratified by presence of chronic bronchitic
symptoms. Compared with CB- group, NCB subjects were
younger (55.4 vs. 57.2 years, p < 0.001) and had a greater
proportion of men (58.5% vs. 53.6%, p Z 0.01). NCB sub-
jects also had a higher BMI and were more frequently cur-
rent smokers with greater pack-year history. Occupational
exposures also differed with NCB subjects reporting with
greater frequency having been exposed at work to dust or
smoke/fumes. FEV1% predicted was slightly lower for NCB
subjects, 89.6% vs. 92.6%, p < 0.001.
Despite the fact that NCB subjects were actually
younger, fewer NCB subjects were actively working. We
also examined comorbidity frequency between groups.
Compared with the CB- group, more NCB participants also
reported history of GERD, sleep apnea, and diabetes. The
difference in cardiovascular disease bordered on statistical
significance. No difference in osteoporosis was seen.
Table 1 Demographics, work history, lung function and comorbidities stratified by presence of chronic bronchitis (nZ 4880).
Chronic bronchitic symptoms
present (n Z 597)
Chronic bronchitic symptoms
absent (n Z 4283)
p-Value
Demographics
Age in years (mean [s.d.]) 55.4 (7.6) 57.2 (8.5) <0.001
Female gender (%) 41.5 46.4 0.02
African American (%) 38.9 40.4 0.47
Education HS and below (%) 41.5 37.9 0.09
BMI in kg/m2 (mean [s.d.]) 30.0 (6.7) 29.1 (6.0) 0.004
Tobacco and occupational exposures
Pack-years smoked (mean [s.d.]) 42.9 (23.1) 37.8 (20.7) <0.001
Currently smokes (%) 79.4 57.2 <0.001
Exposed to dust at job (%) 55.3 42.0 <0.001
Exposed to smoke/fumes at work (%) 52.8 42.2 <0.001
Currently works (%) 29.7 37.3 <0.001
Lung function
FEV1% predicted (mean [s.d.]) 89.6 (16.6) 92.6 (15.2) <0.001
FEV1/FVC (mean [s.d.]) 78.1 (5.4) 78.4 (5.2) 0.23
Comorbidities (%)
Hypertension 41.5 37.7 0.071
Hypercholesterolemia 37.4 35.6 0.404
Gastroesophageal reflux 24.3 19.1 0.003
Sleep apnea 22.3 12.9 <0.001
Diabetes 17.3 12.4 <0.001
Cardiovascular diseasea 13.7 11.0 0.05
Osteoporosis 5.0 5.5 0.64
a Cardiovascular disease includes history of myocardial infarction, coronary artery disease, angioplasty, coronary artery bypass graft,
congestive heart failure, peripheral vascular disease, transient ischemic attack or stroke.
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summarized in Table 2. NCB subjects reported more severe
dyspnea. NCB subjects exhibited poorer (higher) total SGRQ
scores as well as its components. NCB subjects also scored
poorer (lower) for both the SF-36 PCS and SF-36 MCS. The
NCB group walked a shorter distance on the 6MWD test. At
baseline, more NCB subjects reported having had a respi-
ratory event in the prior year treated with antibiotics and/
or steroids than CB- subjects (0.30 vs. 0.10 events/subject,
p < 0.001). Follow-up data for one year or longer were
available in 2897 CB- subjects (67.6%) and 359 NCB subjects
(60.1%), with a mean follow-up period of 2.0 years/patient.
A comparison of participants with at least one year follow-
up with those with less than one year is presented in the
Supplementary Files. During follow-up, NCB subjects also
reported higher annual rate of respiratory events requiring
treatment with either antibiotics or steroids than CB- sub-
jects (0.34 vs. 0.16 annual events/subject, p < 0.001). For
reference, the mean annual per-person exacerbation rate
in COPDGene COPD subjects during the same period was
0.25 for GOLD I and 0.47 for GOLD II subjects. NCB subjects
were also more likely to be on respiratory medications
across all medication classes than CB- subjects. Similar
analyses but adjusted for age, gender, BMI, current smok-
ing, pack-years, FEV1% and clinical center are in Table 4.
The strength and direction of relationships between chronic
bronchitis and dyspnea, 6MWD, SGRQ and SF-36 scores and
respiratory event frequency were all maintained.
Table 3 shows the association of the different hypothe-
sized potential factors associated with the presence ofchronic bronchitis among our non-obstructed cohort in a
logistic regression model additionally adjusted for age,
gender, smoking status, BMI, FEV1% predicted and clinical
center of recruitment. The strongest associations with
chronic bronchitis were current smoking, followed by a
history of sleep apnea, diabetes, and GERD. Occupational
exposure to gas, smoke or chemical fumes at work was also
significantly associated with NCB. Tobacco pack-years and
second hand smoke exposure at work also had small but
statistically significant associations with NCB. African
American race was less likely to be associated with NCB.
The effects of gender and FEV1% were not significant.Discussion
This analysis of a large cross-sectional multicenter study of
current and former smokers without airflow obstruction
demonstrates significant symptoms and morbidity in the
subpopulation who experience chronic bronchitis. Specif-
ically, in analyses adjusted for relevant confounders, we
demonstrate that subjects with NCB (1) report more dys-
pnea and poorer quality of life; (2) demonstrate poorer
exercise capacity; and (3) experience more frequent
treated respiratory events. We also demonstrate that sub-
jects with NCB are less likely to be actively working and
more likely to be on inhaled pharmacologic therapies as
opposed to CB- individuals. Multivariate analysis demon-
strates that the factors with strongest associations with
NCB in this population include current smoking, GERD, OSA
Table 3 Multivariate models to determine factors associated with the presence of non-obstructive chronic bronchitis.a
Model 1 Model 2 Model 3
Current Smoking 2.91 (2.33, 3.63) 3.34 (2.66, 4.20) 3.31 (2.59, 4.24)
African American Race 0.53 (0.43, 0.65) 0.53 (0.43, 0.65)
Age (per year increment) NS NS
Exposed to dust at job 1.37 (1.11, 1.69) 1.34 (1.09, 1.65)
Exposed to smoke at work 1.26 (1.02, 1.54) 1.22 (1.00, 1.50)
Tobacco pack-years 1.00 (1.00, 1.01) 1.00 (1.00, 1.01)
BMI (kg/m2)
Normal or overweight (18.5e29.9) Ref Ref
Underweight (<18.5) NS NS
Obesity (30.0) 1.34 (1.12, 1.60) 1.20 (1.00, 1.45)
FEV1% predicted NS NS
Sleep Apnea 1.53 (1.16, 2.04)
Gastroesophageal Reflux Disease 1.33 (1.07, 1.66)
Diabetes 1.38 (1.07, 1.78)
a Model 1 includes current smoking. Model 2 additionally adjusted for work exposures, demographics and FEV1% predicted. Model 3
additionally adjusted for comorbidities. All models additionally adjusted for clinical center of recruitment.
Table 2 Symptoms burden, and quality of life stratified by presence of chronic bronchitis (n Z 4880).
Chronic bronchitic
symptoms present
(n Z 597)
Chronic bronchitis
symptoms absent
(n Z 4283)
p-Value
Symptoms
MMRC score
MMRC score 0e1 (%) 50.9 78.5 <0.001
MMRC score 2e4 (%) 49.1 21.5
MMRC dyspnea score (mean [s.d.]) 1.6 (1.5) 0.7 (1.1) <0.001
Nasal symptoms 64.8 36.6 <0.001
Ocular symptoms 54.6 33.4 <0.001
Ever previously diagnosed with pneumonia (%) 36.4 25.3 <0.001
Frequency of respiratory “flare-up” in the
year prior to inclusion (mean [s.d.])
0.30 (0.8) 0.10 (0.4) <0.001
Frequency of respiratory “flare-ups”/year
during follow-up (mean [s.d.])b
0.3 (0.7) 0.16 (0.7) <0.001
Functional Status
6MWD in meters (mean [s.d.]) 415 (116) 449 (110) <0.001
Prior Diagnosis of COPD
COPD diagnosed by Health Professional (%) 18.6 6.8 <0.001
Use of Respiratory Medications
Short-acting beta-agonists (%) 17.6 6.5 <0.001
Inhaled corticosteroids (%) 2.9 0.8 <0.001
Long-acting beta-agonists (LABA) (%) 1.2 0.2 <0.001
Combined LABA inhaled corticosteroids (%) 8.8 2.5 <0.001
Long-acting anticholinergics (%) 5.4 2.0 <0.001
QOL Measures (All mean [s.d.])
SGRQ
SGRQ total 35.6 (22.2) 15.1 (16.4) <0.001
SGRQ symptoms 49.8 (20.8) 18.4 (19.1) <0.001
SGRQ activity 45.7 (28.9) 24.4 (25.1) <0.001
SGRQ impact 25.9 (22.2) 8.8 (13.7) <0.001
SF-36a
SF-36 Physical Component 41.8 (10.8) 48.2 (9.7) <0.001
SF-36 Mental Component 43.5 (13.1) 50.4 (10.6) <0.001
a SF-36 was available for 2213 participants.
b Longitudinal follow-up for more than one year available for 359 CBþ and 2897 CB subjects.
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Table 4 Individual adjusted models for symptom and
quality of life measures for presence of non-obstructive
chronic bronchitis.a
Parameter estimate for
presence of non-obstructive
chronic bronchitis (95% CI)
Adjusted modela
MMRC Dyspnea 0.75 (0.65, 0.84)
Distance walked (m) 13.74 (21.45, 6.03)
SGRQ Total 17.11 (15.78, 18.45)
SGRQ Impact 14.56 (13.36, 15.76)
SGRQ Activity 16.42 (14.44, 18.41)
SGRQ Symptoms 27.54 (25.99, 29.10)
bSF-36 PCS 5.20 (6.38, 4.02)
bSF-36 MCS 5.10 (6.44, 3.75)
Fold increase in
treated respiratory
events/year during
follow-upc
2.47 (1.87, 3.27)
a Each model is adjusted for age, gender, BMI, current
smoking, pack-years smoked, FEV1% predicted, and clinical
center of recruitment.
b SF-36 was available for 2213 participants.
c Zero inflated negative binomial model used for respiratory
events, including only those with at least one year follow-up
(n Z 3256); all other models used generalized linear regres-
sion model.
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fumes.
While chronic bronchitis in obstructed individuals has
been previously described and associated with worse QOL
and poorer outcomes [6], the prevalence and significance
of NCB is less well established. Our findings of 13% NCB
frequency among current or former smokers are higher than
reported in other non-COPD cohorts or studies which
included never smokers [22,23], and likely reflects the fact
that our observational study required a 10 pack-year
smoking history as requirement for participation. The
higher frequency of chronic bronchitis in our cohort,
compared with studies within the general population (2.6%
in the European Community Respiratory Health Survey
[ECRHS] [22] and 2.5% in the PLATINO [Proyecto Latin-
oamericano de Investigacion en Obstruccion Pulmonar]
study conducted in South America [23]), underscores the
role of tobacco in the development of CB among our par-
ticipants, even prior to the development of bronchial
obstruction.
We demonstrate significantly poorer symptoms and
quality of life for NCB subjects. The unadjusted mean dif-
ference in SGRQ between those with and without CB was
approximately 20 points which well exceeds the minimal
clinically important difference (MCID) of 4 for SGRQ in
COPD [24]. In fact, the mean SGRQ for NCB subjects is
higher than the reported scores for smokers with no
obstructive physiology [17,18], and is on par with the mean
SGRQ for GOLD Stage II subjects in the COPDGene cohort
(COPDGene cohort mean 33, SD 22; ECLIPSE cohort mean
42, SD 21) [25]. The impact of CB symptoms on QOL extends
beyond disease-specific QOL, as demonstrated by theexistent differences in QOL using generic instruments, such
as SF-36, whose scores were also beyond the MCID. Our
analyses also demonstrated more limited exercise capacity
in NCB subjects with a difference in walk distance of
approximately 34 m which is statistically significant.
Although there is still debate about the MCID for 6MWD in
COPD, with some authors suggesting values of 26e80 m
[26,27], a value of 34 m is within the reported MCID in the
most recent literature among COPD patients [28,29].
Further underscoring the clinical significance of NCB is the
fact that significantly fewer NCB subjects were actively
working as compared to CB- subjects.
NCB subjects also reported respiratory flare-ups treated
with antibiotics or steroids in much greater frequency than
those without. The mean frequency of such events during
longitudinal follow-up was 0.34 events/subject/year as
compared to GOLD I subjects in the COPDGene cohort (0.26
events/subject/year), and close to the reported frequency
of exacerbations requiring treatment in COPD Stage II
participants in the ECLIPSE project (0.37 events/patient/
year) [25]. In addition, nearly 18% of NCB subjects had been
given a diagnosis of COPD by a health professional despite
absence of airflow obstruction on spirometry; almost 9% of
such subjects had been prescribed ICS/LABA combination
therapy, even in the absence of data that such agents can
successfully relieve symptoms or prevent respiratory events
in these individuals.
Participants with NCB had greater pack-year smoking
history and were more frequently current smokers; both
independent risk factors were retained in multivariate
models. Smoking is the most important risk factor for
presence of chronic bronchitis [8,23,30]. However, prior
analysis suggests that differences in smoking habits do not
completely explain the variation in frequency of chronic
bronchitis [22]. While an association between occupational
dust and fumes exposure and chronic bronchitis has previ-
ously been reported [23], we demonstrate that such expo-
sure remains significant in multivariate models adjusted for
smoking and other relevant confounders. A detailed
description of each participant’s job was not included in
the analysis, but every effort was made to identify jobs
with exposure to dust, fumes or smoke. Our current analysis
confirms that sleep apnea and GERD are also independent
and potentially modifiable risk factors for NCB among
smokers. While an association between “bronchitic”
symptoms and OSA have been previously reported [31,32],
these studies were not clearly in subjects without airflow
obstruction. Interestingly, sputum neutrophilia and IL-8
have been reported in subjects with OSA indicating a
relationship between OSA and bronchial inflammation [33].
In a small series of 16 patients, radiologically assessed
bronchial wall thickness was correlated with apnea-
hypopnea index [34]. It has been hypothesized that me-
chanical trauma related to intermittent airway occlusion,
nocturnal hypoxemia leading to ischemia-reperfusion injury
and oxygen free radical production or low-grade systemic
inflammation related to obesity may help to explain this
relationship [35]. An association between GERD and both
COPD and cough have been well established [36], so
perhaps it is not surprising that a relationship should also
exist between GERD and NCB. The mechanism for these
associations is not clear; while it has previously been
Clinical impact of chronic bronchitis in smokers 497suggested that micro-aspiration events might contribute to
this association, recent data suggest this is less likely to be
the case [37]. In any case, further elucidation of the factors
and mechanisms related to NCB, probably a distinct clinical
disorder, is underscored by epidemiologic evidence sug-
gesting that bronchitic symptoms with no airflow limitation
could be an early marker of susceptibility and risk for COPD
[8,38]. Longer follow-up of the current cohort is required to
answer the question about risk of developing COPD.
Our study has several limitations. Our population is
restricted to current or former smokers; therefore the re-
sults cannot be extrapolated to the general population. We
also used a very specific definition for NCB, which includes
cough and sputum production which has been used by
others but cough and sputum were not directly quantified.
Self-report of comorbidities by participants is a potential
limitation of this study. However, the design of the ques-
tions asks for physician-diagnosed conditions, to improve
the certainty of the measurements, a method that in other
surveys has been proved to have high sensitivity and spec-
ificity for prevalent diseases [39]. Our study has the
strength of being a multicenter, large trial collecting a
comprehensive array of clinical, demographic, and func-
tional data.Conclusions
In conclusion, we demonstrate that NCB among current and
former smokers is associated with greater dyspnea, poorer
health status and poorer exercise capacity. NCB subjects
also report more frequent treated respiratory events and
are more likely to not be currently working as opposed to
current and former smokers without chronic bronchitic
symptoms. Longitudinal data will be needed to determine
whether and in which patients NCB progresses to COPD.
However, even in the absence of airflow obstructions, these
individuals have significant symptoms and respiratory
events requiring treatment. Modifiable risk factors we
identified include current smoking in addition to work place
exposures of fumes and smoke. These data would suggest
that preventive measures for NCB patients including as
smoking cessation and appropriate occupational health
precautions may be just as important as they are in in-
dividuals with established airflow obstruction. However,
these data also highlight the need for future investigative
efforts to identify and design potential therapeutic in-
terventions for this patient population.Funding information
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